Dexcom Inc
DXCM
Market Cap$50.37B
Close$
Earnings Call Q4 2023
February 8, 2024 - AI Summary
Dexcom reported strong financial results for the fourth quarter and fiscal year 2023, with total revenue growing by 27% on a reported basis and 26% on an organic basis.
The company added over 600,000 new customers in 2023, ending the year with approximately 2.3 million customers globally.
Dexcom's G7 CGM system has been well-received in the market, driving changes in prescribing patterns and attracting a larger cohort of clinicians to the ecosystem.
Exclusive for Stockcircle Pro members
Sign up
$30.66
76.1% downside
Current Fair Value
76.1% downsideOvervalued by 76.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $50.37 Billion |
|---|---|
| Enterprise Value | $49.96 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $1.5 |
| Beta | 0.88 |
| Outstanding Shares | 397,683,837 |
| Avg 30 Day Volume | 2,995,826 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 78.78 |
|---|---|
| PEG | 39.15 |
| Price to Sales | 14.24 |
| Price to Book Ratio | 25.63 |
| Enterprise Value to Revenue | 13.14 |
| Enterprise Value to EBIT | 76.45 |
| Enterprise Value to Net Income | 78 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 1.11 |
Revenue Sources
No data
ESG Score
No data
About Dexcom Inc
CEO: Kevin Sayer